profit from every $100 of sales.
$0$100
Iridex
$0.71+7.42% today
-33.4% in 1 year
1-year low $0.611-year high $1.56
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Iridex sold, what it kept, and what it did with the cash.
Sales went from $57.0 million in 2022 to $52.7 million in 2025, with -$4.44 million of profit last year.
SalesProfit
Iridex vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Iridex | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Iridex's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 57 | 52 | 49 | 53 | |
| 25 | 22 | 20 | 19 | |
| -8 | -10 | -8 | -3 | |
| -6 | -8 | -7 | -1 | |
| -8 | -10 | -9 | -4 | |
| -0.47 | -0.59 | -0.54 | -0.26 | |
| 44.5% | 42.0% | 40.1% | 36.5% | |
| -13.2% | -19.3% | -17.1% | -4.9% | |
| -13.2% | -18.5% | -18.3% | -8.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 42 | 34 | 29 | 29 |
| Cash | 14 | 7 | 2 | 6 |
| Total debt | 2 | 3 | 5 | 5 |
| Total liabilities | 25 | 25 | 27 | 24 |
| 17 | 10 | 2 | 5 | |
| 16 | 16 | 16 | 17 | |
| -31.4% | -64.4% | -97.3% | -21.5% | |
| -43.8% | -100.5% | -424.9% | -90.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -10 | -7 | -7 | -2 | |
| 0 | 0 | 0 | 0 | |
| -10 | -7 | -7 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 1 | 1 |
Valuation
- –
- –
- –
- 3.7×
- 0.2×
- –
- –
- -18.2%
- -35.8%
- 0.0%
Profitability
- 36.5%
- -4.9%
- -8.4%
- -3.3%
- -17.0%
- -63.4%
- -64.2%
- -11.6%
- -17.4%
- 7.0%
Growth
- −2.6%
- –
- +69.1%
- –
- +2.7%
Financial health
- -1.5×
- 0.90
- 15.1%
- –
- 1.92
- 1.19
- 1.86
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 948
Bottom 18%of 871
Bottom 12%of 868
Bottom 5%of 985
What analysts expect
- Average price target
- $2.75
- Range
- $2.75 – $2.75
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 19, 2026 | -0.03 | -0.07 | +57.1% |
| Mar 26, 2026 | -0.01 | -0.02 | +50.0% |
| Nov 11, 2025 | -0.09 | -0.02 | −350.0% |
| Aug 12, 2025 | -0.06 | -0.09 | +33.3% |
| May 13, 2025 | -0.10 | -0.10 | +0.0% |
| Mar 27, 2025 | -0.05 | -0.05 | +0.0% |
| Nov 12, 2024 | -0.12 | -0.09 | −33.3% |
| Aug 8, 2024 | -0.16 | -0.12 | −33.3% |
News
Iridex reaffirms 2026 revenue guidance of $51m-$53m while highlighting working-capital build tied to headquarters relocationSeeking Alpha · Aug 19, 2026The newest story we have is from Aug 19, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
25No pass
Philip Fisher
30No pass
Peter Lynch
20No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
19No pass
Questions about Iridex
Is Iridex a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Iridex AI analysis
What does Iridex do?
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It is in Medical - Devices.
Does Iridex pay a dividend?
No. Iridex does not pay a dividend at the moment.
Is Iridex stock halal?
No. Iridex does not pass our halal screen: its debt is 37% of its market value, at or above the 33% limit. How we check
How has Iridex stock done over the past year?
Down 33.4% over the past twelve months, to $0.71. It traded between $0.61 and $1.56 and is 54.7% below its high.
Who are Iridex's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Iridex's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.